The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease

Published:September 17, 2022DOI:



      The effectiveness of Ustekinumab (UST) and Vedolizumab (VDZ) in patients with Crohn's disease (CD) as third-line biologic therapies is unclear.


      We performed a multicentre, real-world assessment of the effectiveness of UST and VDZ among highly-refractory patients with CD.


      Data of consecutive patients with CD treated with UST and VDZ as third-line biologic therapy until December 2021 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).


      143 patients (UST: n = 113; VDZ: n = 30) were included. At the end of induction, the rates of clinical response (CR) were 61.9% for UST and 60.0% for VDZ (p = 1.00), with steroid-free clinical remission (SFCR) achieved in 38.1% of patients in the UST group and 43.3% of patients in the VDZ group (p = 0.75). After 52 weeks of observation, the rates of CR were 65.9% for UST and 71.4% for VDZ (p = 0.77), while the rates of SFCR were 51.8% for UST and 57.1% for VDZ (p = 0.78). At multiple Cox proportional hazard regression model, age (HR 0.98; p = 0.04) and need for systemic steroids at baseline (HR 3.29; p = 0.003) were found to be independent predictors of treatment discontinuation.


      Both VDZ and UST showed high effectiveness as third-line biologic therapy in CD, without significant differences between them.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Juillerat P.
        • Grueber M.M.
        • Ruetsch R.
        • et al.
        Positioning biologics in the treatment of IBD: a practical guide - which mechanism of action for whom?.
        Curr Res Pharmacol Drug Discov. 2022; 3100104
        • Macaluso F.S.
        • Maida M.
        • Ventimiglia M.
        • et al.
        Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies.
        Expert Opin Biol Ther. 2020; 20: 193-203
        • Schreiber S.
        • Dignass A.
        • Peyrin-Biroulet L.
        • et al.
        Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
        J Gastroenterol. 2018; 53: 1048-1064
        • Macaluso F.S.
        • Maida M.
        • Grova M.
        • et al.
        Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience.
        Therap Adv Gastroenterol. 2021; 1417562848211010668
        • Armuzzi A.
        • Fiorino G.
        • Variola A.
        • et al.
        The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy.
        Inflamm Bowel Dis. 2019; 25: 568-579
        • Macaluso F.S.
        • Fries W.
        • Viola A.
        • et al.
        The SPOSIB SB2 sicilian cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches.
        Inflamm Bowel Dis. 2021; 27: 182-189
        • Macaluso F.S.
        • Cappello M.
        • Busacca A.
        • et al.
        SPOSAB ABP 501: a sicilian prospective observational study of patients with inflammatory bowel disease treated with adalimumab biosimilar ABP 501.
        J Gastroenterol Hepatol. 2021; 36: 3041-3049
        • Parrot L.
        • Dong C.
        Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
        Aliment Pharmacol Ther. 2022; 55: 380-388
        • Alric H.
        • Amiot A.
        • Kirchgesner J.
        • et al.
        The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
        Aliment Pharmacol Ther. 2020; 51: 948-957
        • Manlay L.
        • Boschetti G.
        • Pereira B.
        • et al.
        Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
        Aliment Pharmacol Ther. 2021; 53: 1289-1299
        • Biemans V.B.C.
        • van der Woude C.J.
        • Dijkstra G.
        • et al.
        Dutch Initiative on Crohn and Colitis (ICC). Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
        Aliment Pharmacol Ther. 2020; 52: 123-134
        • Townsend T.
        • Razanskaite V.
        • Dodd S.
        • et al.
        Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
        Aliment Pharmacol Ther. 2020; 52: 1341-1352
        • Kolář M.
        • Ďuricová D.
        • Bortlík M.
        • et al.
        Vedolizumab vs. ustekinumab as second-line therapy in Crohn's disease in clinical practice.
        Gastroenterol Hepatol. 2019; 73: 25-31
        • Lenti M.V.
        • Dolby V.
        • Clark T.
        • et al.
        A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
        Aliment Pharmacol Ther. 2021;
        • Onali S.
        • Pugliese D.
        • Caprioli F.A.
        • IG-IBD ;.
        Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors.
        Am J Gastroenterol. 2022;
        • Albshesh A.
        • Taylor J.
        • Savarino E.V.
        Effectiveness of third-class biologic treatment in Crohn's disease: a multi-center retrospective cohort study.
        J Clin Med. 2021; 10: 2914
        • Kassouri L.
        • Amiot A.
        • Kirchgesner J.
        • et al.
        The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
        Dig Liver Dis. 2020; 52: 1148-1155
        • Singh S.
        • Murad M.H.
        • Fumery M.
        • et al.
        Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
        Lancet Gastroenterol Hepatol. 2021; 6: 1002-1014